|
Market Closed -
Euronext Paris
23:55:00 02/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 6.610 EUR | -7.38% |
|
-10.59% | -60.77% |
| Market Cap | 68.12M 76.65M 63.49M 57.86M 109M 7.38B 110M 770M 298M 3.74B 288M 282M 12.09B | P/E 2026 * |
-1.87x | P/E 2027 * | -2.86x |
|---|---|---|---|---|---|
| Enterprise Value | -5.88M -6.62M -5.48M -5M -9.43M -638M -9.52M -66.54M -25.77M -323M -24.87M -24.33M -1.04B | EV / Sales 2026 * |
-1.54x | EV / Sales 2027 * | -0.46x |
| Free-Float |
65.24% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ALSEN | Real-time | |
Börse Stuttgart
| RFM | Delayed | |
|
Börse Stuttgart
| RFM | Delayed | |
|
Boerse Muenchen
| RFM | Real-time | |
|
CBOE
| Real-time | ||
|
CBOE
| Real-time | ||
|
Deutsche Boerse AG
| RFM | Delayed | |
|
Boerse Muenchen
| RFM | Real-time | |
|
CBOE
| Real-time | ||
|
CBOE
| Real-time | ||
|
Tradegate
| RFM | Real-time |
| 1 day | -7.38% | ||
| 1 week | -10.59% | ||
| Current month | -9.25% | ||
| 1 month | -48.36% | ||
| 3 months | -49.15% | ||
| 6 months | -68.37% | ||
| Current year | -60.77% |
| 1 week | 6.49 |  | 8.24 |
| 1 month | 6.49 | | 12.85 |
| Current year | 6.49 | | 40.4 |
| 1 year | 6.49 | | 40.4 |
| 3 years | 6.49 | | 52 |
| 5 years | 6.49 | | 114.5 |
| 10 years | 6.49 | | 387 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frédéric Chéreau
CEO | Chief Executive Officer | 59 | 01/06/2026 |
Laurene Danon
DFI | Director of Finance/CFO | - | 26/06/2024 |
Bernd Schmidt
CTO | Chief Tech/Sci/R&D Officer | - | 11/12/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 09/03/2015 | |
Julien Miara
BRD | Director/Board Member | 43 | - |
Khalil Barrage
CHM | Chairman | 61 | 30/03/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/2/26 | Redmile Biopharma Investments III LP
| Buy | Company | 18,928,571 | 6.2956% | |
| 31/1/26 | Sofinnova Partners SAS
| Buy | Company | 10,714,285 | 3.5636% | |
| 18/4/24 | Redmile Biopharma Investments III LP
| Buy | Company | 2,781,914 | 1.0091% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.38% | -10.59% | -64.46% | -80.21% | 76.66M | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.16B | |
| -3.11% | -3.53% | +20.19% | +81.44% | 57.39B | |
| +0.89% | -0.63% | +2.17% | +36.19% | 47.64B | |
| +0.36% | +0.81% | +342.39% | +742.40% | 44.29B | |
| -0.96% | -4.50% | +24.96% | +35.38% | 42.5B | |
| -0.20% | -0.77% | +4.13% | +105.50% | 40.71B | |
| -0.54% | +2.93% | +9.31% | +50.41% | 30.97B | |
| -2.68% | +2.92% | +29.33% | +22.72% | 28.53B | |
| +0.05% | -1.64% | -8.14% | -11.37% | 24.34B | |
| Average | -0.94% | -1.59% | +40.92% | +107.66% | 39.06B | |
| Weighted average by Cap. | +0.12% | -0.84% | +56.93% | +138.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.83M 4.31M 3.57M 3.25M 6.14M 415M 6.19M 43.28M 16.76M 210M 16.18M 15.83M 679M | 15M 16.88M 13.98M 12.74M 24.04M 1.62B 24.26M 170M 65.69M 823M 63.39M 62.02M 2.66B |
| Net income | -36M -40.51M -33.56M -30.58M -57.72M -3.9B -58.23M -407M -158M -1.98B -152M -149M -6.39B | -28.79M -32.39M -26.83M -24.45M -46.15M -3.12B -46.56M -326M -126M -1.58B -122M -119M -5.11B |
| Net Debt | -74M -83.27M -68.98M -62.86M -119M -8.02B -120M -837M -324M -4.06B -313M -306M -13.13B | -75M -84.4M -69.91M -63.71M -120M -8.13B -121M -848M -328M -4.12B -317M -310M -13.31B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/10/26 | €6.610 | -7.38% | 42,691 |
| 01/10/26 | €7.137 | -2.02% | 15,952 |
| 30/09/26 | €7.284 | -7.04% | 24,690 |
| 29/09/26 | €7.836 | -0.94% | 22,603 |
| 28/09/26 | €7.910 | +6.99% | 33,110 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALSEN Stock
Select your edition
All financial news and data tailored to specific country editions
